טוען...
Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
The successes of checkpoint blockade immunotherapy (CBI) and BRAF(V600)-targeted therapy trials have generated substantial promise for revolutionizing the management of patients with advanced melanoma. However, because early clinical trials of CBIs and BRAF(V600)-targeted therapy either excluded or...
שמור ב:
| הוצא לאור ב: | Cancer Immunol Res |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6230261/ https://ncbi.nlm.nih.gov/pubmed/30002157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0067 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|